Austria
• Program leader for the development of retatrutide. • Clinical program leader for the research of the mechanism of action of retatrutide.
• Program leader for dual and triple-action oral and injectable incretin receptor agonists. • Clinical program leader for the mechanism of action research program for the dual receptor agonist tirzepatide. • Clinical leader for the early development of retatrutide, a triple-action incretin receptor agonist. • Overall strategy for programs related to dual and triple incretin receptor agonists tirzepatide and retatrutide, as well as the oral GLP-1 receptor agonist orforglipron.
• Key responsibilities: global medical and regulatory strategy for drug approval, strategy leader for drug approval in the EU. • Responsible for the design and implementation of registration clinical trials. • Strategy for collaboration with key experts and implementation of the plan.
• Head of the Metabolic Diseases Department. • Head of the Department for Clamp Procedure Applications in Metabolic Research.